Advanced Renal Cell Carcinoma Treatment Market: Current Analysis and Forecast (2022-2028)

$3999$6999

Emphasis on Treatment (Chemotherapy, Biologics, and Others); Route of Administration (oral, parenteral, and other); End-Use (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy); and Region/Country

Pages:

158

Table:

46

Figure:

104

Report ID:

UMHE211625

Geography:

Clear
  Get a Sample
SKU: UMHE211625 Categories: , Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Report Description
Table of content
Research Methodology

Report Description

Advanced Renal Cell Carcinoma Treatment Market
Advanced Renal Cell Carcinoma Treatment Market

Global Advanced Renal Cell Carcinoma Treatment Market is expected to grow at a significant rate of around 5% during the forecast period. The growth in the market is due to the wide availability of novel drugs, the surge in the prevalence of renal cancer, and the presence of a robust pipeline. Apart from this, the surge in the geriatric population and the high adoption of a sedentary lifestyle are mounting the incidences of renal cell carcinoma. The key players in the advanced renal cell carcinoma treatment market are utilizing advancements in technology to launch new products and gain a competitive advantage. These pharmaceutical giants are continually investing in research and development activities to keep themselves in tandem with the changing consumer preferences and end-use industry demands. For instance, in February 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Opdivo in combination with Cabometyx or the first-line treatment of adults with advanced renal cell carcinoma.

Bristol-Myers Squibb Company; Novartis AG; Pfizer Inc.; Genentech, Inc; GSK plc.; Bayer AG; Eisai Co., Ltd; Exelixis, Inc.; Merck KGaA; NiKang Therapeutics, Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report

“Amongst route of administration, parenteral category to hold a significant share in the market in 2020”

Based on the route of administration, the market is categorized into oral, parenteral, and other. The oral route held a significant share of the market in 2020. The parenteral category held a significant share in the market in 2020. The parenteral administration refers to the introduction of substances into the body by routes other than the gastrointestinal tract but practically the term is applied to the injection of substances in form of solution or suspension into the body at various sites and to varying depths using a needle and a syringe. It is one of the fastest routes of administration and administers the medication at the target site, thus avoiding any side-effect. Thus, these factors are propelling the segment growth in coming years.

“Amongst treatment, the biologics category to witness higher CAGR during the forecast period”

On the basis of treatment, the market is segmented into chemotherapy, biologics, and others. The biologics segment is expected to grow with a high CAGR during the forecast period as it is aimed at the disease while reducing the side effects to normal cells. Moreover, the rising product pipeline and rapid drug approval are anticipated to drive segment growth during the forecast period. For instance, in 2022, Exelixis initiated STELLAR-304 trial, which aims to evaluate zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced non-clear cell renal cell carcinoma. Apart from this, the patent expiration of biologics opens new opportunities for the development of cost-effective biosimilar drugs. For example, NeuClone is currently developing biosimilar products for Opdivo and Keytruda. Thus, these factors will have a positive impact on the segment growth during the forecast period.

“Amongst end-use, the online pharmacy category to witness higher CAGR during the forecast period”

On the basis of end-use, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The online pharmacy is expected to witness higher CAGR during the forecast period which is attributed to the surge in the number of internet users, widening access to online services, and the increase in the e-prescriptions in hospitals and other healthcare settings. In addition, the spur in the initiative taken by governments as well as private entities toward e-pharmacy also drives the regional market growth. For instance, in August 2020, Reliance Retail Limited acquired around 60% stakes in Netmeds Marketplace Ltd. to enhance the affordability of superior quality healthcare products to consumers through online mode.

“North America to hold a significant share in the market”

In 2020, North America held a significant share of the global advanced renal cell carcinoma treatment market owing to the surge in the prevalence of advanced renal cell carcinoma, and the increasing accessibility of novel technology in cancer research and treatment facilities. For instance, in February 2022, American Society of Clinical Oncology (ASCO), 2022, an estimated 79,000 adults (50,290 men and 28,710 women) in the U.S. would be diagnosed with kidney cancer. Apart from this, other factors such as a rise in product approval, increased adoption of therapeutics, and the presence of major key players are also boosting the growth of the market. For instance, in November 2021, U.S. FDA approved Keytruda for the adjuvant treatment of patients with advanced RCC.

Reasons to buy this report:

  • The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
  • The report presents a quick review of overall industry performance at one glance.
  • The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
  • Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
  • The study comprehensively covers the market across different segments.
  • Deep dive regional level analysis of the industry.


Customization Options:

The global advanced renal cell carcinoma treatment market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

You can also purchase parts of this report. Do you want to check out a section wise
price list?

1.1.Market Definitions
1.2.Main Objective
1.3.Stakeholders
1.4.Limitation
2.1.Research Process of the Advanced Renal Cell Carcinoma Treatment Market
2.2.Research Methodology of the Advanced Renal Cell Carcinoma Treatment Market
2.3.Respondent Profile
3MARKET SYNOPSIS
4EXECUTIVE SUMMARY
5IMPACT OF COVID-19 ON THE ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET
6ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET REVENUE (USD BN), 2020-2028F
7.1.Chemotherapy
7.2.Biologics
7.3.Others
8.1.Oral
8.2.Parenteral
8.3.Other
9.1.Hospital Pharmacy
9.2.Retail Pharmacy
9.3.Online Pharmacy
10.1.North America  
 10.1.1.U.S.
 10.1.2.Canada
 10.1.3.Rest of North America
10.2.Europe  
 10.2.1.Germany
 10.2.2.U.K.
 10.2.3.France
 10.2.4.Italy
 10.2.5.Spain
 10.2.6.Rest of Europe
10.3.Asia-Pacific 
 10.3.1.China
 10.3.2.Japan
 10.3.3.India
 10.3.4.Rest of Asia-Pacific
10.4.Rest of World 
11.1.Market Drivers
11.2.Market Challenges
11.3.Impact Analysis
12ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET OPPORTUNITIES
13ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET TRENDS
14.1.Demand Side Analysis
14.2.Supply Side Analysis
15VALUE CHAIN ANALYSIS
16.1.Competitive Landscape
 16.1.1.Porters Fiver Forces Analysis
17.1.Bristol-Myers Squibb Company
17.2.Novartis AG
17.3.Pfizer Inc.
17.4.Genentech, Inc
17.5.GSK plc. 
17.6.Bayer AG 
17.7.Eisai Co., Ltd
17.8.Exelixis, Inc.
17.9.Merck KGaA
17.10.NiKang Therapeutics, Inc.
18DISCLAIMER

Research Methodology

Research Methodology for the Advanced Renal Cell Carcinoma Treatment Market Analysis (2022-2028)

Analyzing the historical market, estimating the current market, and forecasting the future market of the global advanced renal cell carcinoma treatment market were the three major steps undertaken to create and analyze the adoption of advanced renal cell carcinoma treatment in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global advanced renal cell carcinoma treatment market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:

Analysis of Historical Market Size

Step 1: In-Depth Study of Secondary Sources:

Detail secondary study was conducted to obtain the historical market size of the advanced renal cell carcinoma treatment market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.

Step 2: Market Segmentation:

After obtaining the historical market size of the advanced renal cell carcinoma treatment market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as animal type, route of administration, indication, and distribution. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.

Step 3: Factor Analysis:

After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the advanced renal cell carcinoma treatment market. Further, we conducted factor analysis using dependent and independent variables such as various treatment, route of administration, and end-use of advanced renal cell carcinoma treatment. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the advanced renal cell carcinoma treatment market sector across the globe.

Current Market Size Estimate & Forecast

Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global advanced renal cell carcinoma treatment market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.

Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2028 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:

  • The industry’s market size, in terms of revenue (USD) and the adoption rate of the advanced renal cell carcinoma treatment market across the major markets domestically
  • All percentage shares, splits, and breakdowns of market segments and sub-segments
  • Key players in the global advanced renal cell carcinoma treatment market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market


Market Size and Share Validation

Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.

Split of Primary Participants in Different Regions

Advanced Renal Cell Carcinoma Treatment Market
Advanced Renal Cell Carcinoma Treatment Market

Market Engineering

The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global advanced renal cell carcinoma treatment market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of product, technology, application, and end-use in the global advanced renal cell carcinoma treatment market.

The main objective of the Global Advanced Renal Cell Carcinoma Treatment Market Study

The current & future market trends of the global advanced renal cell carcinoma treatment market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:

  • Analyze the current and forecast market size of the advanced renal cell carcinoma treatment market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
  • Segments in the study include areas of treatment, route of administration, and end-use.
  • Define and analysis of the regulatory framework for the advanced renal cell carcinoma treatment industry.
  • Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
  • Analyze the current and forecast market size of the advanced renal cell carcinoma treatment market for the major region.
  • Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World.
  • Company profiles of the advanced renal cell carcinoma treatment market and the growth strategies adopted by the market players to sustain in the fast-growing market
  • Deep dive regional level analysis of the industry

You can also purchase parts of this report. Do you want to check out a section wise
price list?